{
  "drug_id": "D001",
  "drug_name": "Amegena",
  "indication": "Condition-X",
  "modality": "small molecule",
  "mechanism": "ligand neutralizing antibody",
  "moa_short": "Neutralizes a circulating ligand to reduce pathway activation.",
  "formulation": "tablet",
  "route": "oral",
  "regimen": "150 mg BID",
  "trial_id": "AMGN-D001-201",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Amegena 150 mg BID",
      "n": 240,
      "dose": "150 mg BID"
    },
    {
      "name": "Placebo",
      "n": 254,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Condition-X with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Mean change in Composite Index at Week 24",
    "endpoint_secondary": "Durable response at Week 24",
    "primary_effect": "LS mean difference -0.93 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.011865327252205808,
    "primary_ci": "[-1.33, -0.53]",
    "secondary_effect": "Met nominal significance in hierarchical testing",
    "discontinuation_rate_pct": 3.6286988121715704
  },
  "safety": {
    "common_ae": [
      [
        "Diarrhea",
        13.877745594595824
      ],
      [
        "Injection-site reaction",
        12.776956548642483
      ],
      [
        "Fatigue",
        9.802839548396165
      ],
      [
        "Elevated ALT",
        9.647471631684706
      ],
      [
        "Dizziness",
        4.516380532185682
      ],
      [
        "Upper respiratory infection",
        5.131861175625088
      ]
    ],
    "serious_ae_rate_pct": 2.6757889422657906,
    "discontinuation_ae_rate_pct": 3.738722328547789,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v1.9",
  "doc_date": "2025-12-26"
}